Biotech Analyst Brayer, along with Dr. Armeen Poor, Asst Professor of Medicine & Attending Pulmonary Physician at Metropolitan Hospital Center, discuss Regeneron/Sanofi’s upcoming Phase 3 Readout for Dupixent in COPD (1Q23) on an Analyst/Industry conference call to be held on March 1 at 1 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
- Regeneron and Sanofi’s Kevzara approved by FDA for polymyalgia rheumatica
- Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
- Regeneron says CHMP adopts positive opinion on Libtayo with chemotherapy
- Regeneron announces U.S. FDA accepted priority review for BLA for aflibercept